Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
CC transcript
Asset disposition
Quarterly results
ALLIANCEBERNSTEIN HOLDING L.P. (AB)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
04/29/2021
GN
AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint
04/29/2021
GN
AB Science annonce aujourd'hui que l'étude de phase 2B/3 (AB12003) du masitinib dans le cancer de la prostate métastatique hormono-résistant (mCRPC) a atteint son critère d'évaluation principal prédéfi
04/06/2021
GN
AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19
04/06/2021
GN
AB Science annonce aujourd'hui la signature d'un accord de licence exclusif avec l'Université de Chicago sur la prévention et le traitement de la Covid-19
03/31/2021
GN
AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer
03/08/2021
GN
AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders including Alzheimer's Disease
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy